Harbin Pharmaceutical Group , Ltd. Receivables

The latest receivables for 600664.SS is $5.4B as of June 2026. That compares with $5.1B in the prior-year period — up 5.4% year over year. Investors often review this figure alongside Harbin Pharmaceutical Group , Ltd.'s historical trend and sector peers before judging valuation or financial health.

Over the past year, 600664.SS's receivables moved from $5.1B to $5.4B — a 5.4% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Harbin Pharmaceutical Group , Ltd.'s operating scale or balance-sheet position.

A receivables figure of $5.4B for 600664.SS is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting 600664.SS's receivables ($5.4B), review year-over-year change from $5.1B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.